Evidence map›Paper›PMID 38980957›Full record

ArticleAngewandte Chemie (International ed. in English)2024

Half-Curcumin-Based Chemiluminescence Probes and Their Applications in Detecting Quasi-Stable Oxidized Proteins.

Jun Yang, Biyue Zhu, Jing Zhang, Steven H Liang, Shiqian Shen, Chongzhao Ran

Abstract read
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jun YangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Boston, Massachusetts, USA, 02129.
Biyue ZhuAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Boston, Massachusetts, USA, 02129.
Jing ZhangAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Boston, Massachusetts, USA, 02129.
Steven H LiangDepartment of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia, 30322, United States.
Shiqian ShenMassachusetts General Hospital Center for Translational Pain Research, Department of Anesthesia, Critical Care and Pain Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
Chongzhao RanAthinoula A. Martinos Center for Biomedical Imaging, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Charlestown, Boston, Massachusetts, USA, 02129.ORCID 0000-0002-3892-4108

Funding

Development of sensitive PET tracers of pan-Amyloid-beta species for Alzheimer's diseaseR01AG085562 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI Chongzhao Ran · 2024 to 2026
$2.5M
Near infrared fluorescence imaging of reactive oxygen species in Alzheimer's diseaseR01AG055413 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2018 to 2022
$2.1M
Upgrade and replacement of IVIS Spectrum imaging systemS10OD028609 · OD · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2020 to 2020
$600k
Differentiating Abeta40/42 in plaques with small molecule fluorescent probesR21AG078749 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2022 to 2022
$459k
Near infrared Fluorescence Ocular Imaging of Soluble Amyloid Beta SpeciesR21AG059134 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI RAN, CHONGZHAO · 2018 to 2019
$459k
PET Imaging for neuroinflammation in Alzheimer's diseaseR21AG074218 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI LIANG, STEVEN H · 2021 to 2022
$442k
PET imaging for neuroimmune function in Alzheimer's diseaseR21AG078058 · NIA · EMORY UNIVERSITY · PI LIANG, STEVEN H · 2022 to 2022
$430k
PET imaging of ionotropic glutamate receptor signaling in Alzheimer's diseaseR21AG080262 · NIA · EMORY UNIVERSITY · PI LIANG, STEVEN H · 2023 to 2024
$430k
Foundation for the National Institutes of Health R01AG055413Foundation for the National Institutes of Health R01AG085562Foundation for the National Institutes of Health R21AG059134Foundation for the National Institutes of Health R21AG074218Foundation for the National Institutes of Health R21AG078749Foundation for the National Institutes of Health R21AG079058Foundation for the National Institutes of Health R21AG080262Foundation for the National Institutes of Health S10OD028609NIA NIH HHS R01 AG055413NIA NIH HHS R01 AG085562NIA NIH HHS R21 AG059134NIA NIH HHS R21 AG074218NIA NIH HHS R21 AG078058NIA NIH HHS R21 AG078749NIA NIH HHS R21 AG080262NIH HHS S10 OD028609
6 · The paper itself

Abstract

Numerous methods have been reported for detecting ROS/RNS in vitro and in vivo; however, detecting methods for the secondary products of the reactive oxygen species (ROS)/reactive nitrogen species (RNS) reactions, particularly quasi-stable oxidized products, have been much less explored. In this report, we observed that half-curcumins could generate chemiluminescence (CL). In contrast to other chemiluminescence scaffolds, the distinguishing feature of a half-curcumin is the formation of a carbanion intermediate of its acetylacetone moiety, opening unique avenues for applications. In this study, we designed a series of half-curcumins CRANAD-Xs and found that CRANAD-164 could be used to detect quasi-stable oxidized proteins (QSOP) in vivo and in patient serum samples. We illustrated that CRANAD-164 could be used to monitor the responses of taurine, an amino acid with newly reported anti-aging capacity, in an inflammatory mouse model. Remarkably, we further demonstrated that the QSOP levels were much higher in the disease serum samples, including Alzheimer's disease (AD), compared to the samples from healthy controls. Moreover, our results revealed that the sera chemiluminescence intensities were higher in aged healthy controls compared to young healthy subjects, suggesting that CRANAD-164 can be used to monitor the increase of QSOP during aging.

Indexed as

CurcuminLuminescent MeasurementsOxidation-ReductionAlzheimer DiseaseAnimalsHumansLuminescenceLuminescent AgentsMiceMolecular StructureReactive Oxygen SpeciesCurcuminLuminescent AgentsReactive Oxygen Specieschemiluminescencecurcuminin vivo imagingliquid biopsyQuasi-stable oxidized proteins

Identifiers

PMID38980957
PMCPMC11421953

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.